Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan最新文献

{"title":"Intranasal essential oils in therapy: advances in clinical applications and delivery mechanisms.","authors":"Liang Yong, Guan Qiuyan, Chen Yi, W U Wei, Yang Ming, Tang Fangrui, Wang Yawen, Pan Deng, Huang Xiaoying, L I Huiting","doi":"10.19852/j.cnki.jtcm.2026.04.022","DOIUrl":"10.19852/j.cnki.jtcm.2026.04.022","url":null,"abstract":"<p><p>This review comprehensively examines the therapeutic mechanisms, formulation advancements, and clinical applications of intranasal essential oil (EO) delivery, aiming to highlight its potential as a modern therapeutic approach. A systematic literature search was conducted in PubMed and Web of Science up to May 2024, focusing on preclinical and clinical studies. Data on target diseases, delivery mechanisms, formulation innovations, and therapeutic effects were extracted and analyzed. Intranasal EO delivery demonstrates significant therapeutic potential for neurological, respiratory, cardiovascular, and metabolic disorders. Advanced delivery systems, including nanoemulsions, liposomes, and nasal in situ gels, enhance EO stability, bioavailability, and targeted release. Mechanistically, EOs exert effects through neurotransmission modulation, anti-inflammatory pathways, and vascular regulation, primarily <i>via</i> the olfactory and trigeminal nerves. Clinical evidence supports the efficacy of intranasal EOs in conditions such as anxiety, depression, allergic rhinitis, and hypertension, although further optimization is needed to minimize irritation and improve patient adherence. Intranasal delivery of EOs offers a promising strategy for enhancing therapeutic administration and expanding clinical applications. Future research should focus on developing advanced <i>in vivo</i> pharmacokinetic evaluation tools, optimizing delivery systems, ensuring safety, and integrating EOs with conventional therapies to support their broader clinical translation.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"46 4","pages":"1026-1041"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Heshu Xiaoji pills combined with standard treatment strategy in hepatitis B virus-related hepatocellular carcinoma: a single-center, open-label, prospective controlled, real-world cohort study.","authors":"Zhu Xiaoning, Yin Yue, Kong Yuan, Peng Mengyun, Peng Zhaoxuan, Zheng Ding, Wang Xiaodong, Han Yunwei, L I Bo, Liu Jurong, Wang Encheng, Tian Zhen, Peng Qinghua, Jiang Yuanyuan, M I Shaoping, Liu Yong, P U Qingrong, Guo Yongcan, H E Qizhou, Cheng Chunxia, L I Linghua, Jia Hong, Wang Jing","doi":"10.19852/j.cnki.jtcm.2026.04.016","DOIUrl":"10.19852/j.cnki.jtcm.2026.04.016","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effectiveness and safety of Heshu Xiaoji pills (HSXJ, ) as an adjunct to standard treatment in patients with hepatitis B virus-related hepatocellular carcinoma.</p><p><strong>Methods: </strong>Overall, 201 patients enrolled between May 2020 and February 2022 received either HSXJ plus standard treatment (TCM group, <i>n =</i> 136) or standard treatment alone (Control group, <i>n =</i> 65). Follow-up continued until February 2023. Propensity score matching (PSM) (2∶1) was used to adjust for baseline differences, yielding 61 TCM and 39 control patients. Overall survival (OS), progression-free survival (PFS), and safety were compared using multivariate Cox proportional hazard regression.</p><p><strong>Results: </strong>Before PSM, OS and PFS were significantly longer in the TCM group than in the Control group (OS: 609 <i>vs</i> 500 d; PFS: 609 <i>vs</i> 507 d). After PSM, PFS remained significantly longer (551 <i>vs</i> 449.5 d), but OS differences were not statistically significant. Adverse events were comparable between groups. Subgroup analysis identified patients with cirrhosis, prior resection or local therapy, Child-Pugh A stage, HBV-DNA ≥ 2000 IU/mL, and alpha-fetoprotein ≤ 200 ng/mL as the most responsive to this TCM therapy.</p><p><strong>Conclusions: </strong>HSXJ combined with standard treatment strategy significantly improved PFS in patients with HBV-related HCC without added safety risks.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"46 4","pages":"961-971"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of a nomogram for anxiety and depression in patients with Sjögren's syndrome by combining tongue and pulse characteristics: a cross-sectional study based on a prospective cohort.","authors":"Shan Xueyan, H E Jiale, Guo Zilin, Pang Fengtao, Liu Ruihua, Liu Ying, Jiang Ping, J I Wei, Y U Jing, Zhou Xinyao, Tang Xiaopo","doi":"10.19852/j.cnki.jtcm.2026.04.017","DOIUrl":"10.19852/j.cnki.jtcm.2026.04.017","url":null,"abstract":"<p><strong>Objective: </strong>To develop and validate a predictive model for predicting psychological complications of Sjögren's syndrome (SS) in combination with tongue and pulse characteristics.</p><p><strong>Methods: </strong>This cross-sectional study was based on a prospective cohort study including SS patients recruited from 30 major tertiary hospitals in China. Nomograms were developed based on the clinical characteristics, tongue and pulse manifestations, and laboratory tests of these patients, and univariate and multivariate logistic regression analyses were used to screen for various correlates of anxiety and depression, and the column charts were evaluated using the area under the curve (AUC), calibration curves, and decision curve analysis.</p><p><strong>Results: </strong>A total of 444 patients were included, comprising 424 females (95.5%) and 20 males (4.5%), with a mean age of (46 ± 13) years. The prevalence of anxiety and depression was 45.5% (<i>n =</i> 202) and 42.1% (<i>n =</i> 187), respectively. Peeled tongue was associated with higher rates of both anxiety and depression among SS patients [odds ratio (<i>OR</i>) for anxiety = 0.44, 95% <i>CI</i> (0.26, 0.74), <i>P =</i> 0.002; <i>OR</i> for depressio<i>n =</i> 0.44, 95% <i>CI</i> (0.27, 0.73), <i>P =</i> 0.002]. Regarding pulse diagnostics, a thready pulse was linked to increased anxiety [<i>OR</i>= 1.99, 95% <i>CI</i>(1.11, 3.60), <i>P =</i> 0.022], while a slippery pulse correlated with depression [<i>OR</i> = 0.32, 95% <i>CI</i>(0.14, 0.74), <i>P =</i> 0.007]. Nomograms developed from these findings demonstrated good predictive performance, with AUC values of 0.767 for anxiety and 0.741 for depression in both training and validation cohorts.</p><p><strong>Conclusions: </strong>Integrating Traditional Chinese Medicine diagnostics with conventional clinical assessments provides a robust predictive model for psychological comorbidities in SS. The innovative approach enhances personalized management, offering a pathway for targeted interventions to treat anxiety and depression effectively in affected patients.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"46 4","pages":"972-981"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of acupuncture and moxibustion combined with core stabilization training on the function of transverse abdominal muscle and pelvic floor muscle in women with postpartum pelvic pain.","authors":"Shi Ling, Yang Chengcheng, Huang Li, Deng Linwen","doi":"10.19852/j.cnki.jtcm.2026.04.020","DOIUrl":"10.19852/j.cnki.jtcm.2026.04.020","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy of acupuncture and moxibustion combined with core stabilization exercises (CSE) in enhancing the function of the transverse abdominal muscle (TAM) and pelvic floor muscle in postpartum women with pelvic pain.</p><p><strong>Methods: </strong>This retrospective cohort study included 205 postpartum women with moderate to severe pelvic pain [visual analog scale (VAS) score ≥ 4] between January 2020 and January 2022. Participants were allocated to either a control group receiving CSE (<i>n</i>= 93) or a joint treatment group receiving CSE with acupuncture and moxibustion (<i>n =</i>112). Outcomes assessed included pain relief (VAS), TAM thickness (ultrasound measurement), pelvic floor muscle recovery (manual assessment), urinary incontinence pad test, international consultation on incontinence questionnaire-short form, incontinence quality of life questionnaire, sexual satisfaction (validated questionnaire), quality of life world health organization quality of life questionnaire-abbreviated version, and depression (Self-Rating Depression Scale).</p><p><strong>Results: </strong>Both groups experienced significant reductions in pelvic pain, with superior outcomes noted in the joint treatment group (<i>P =</i>0.008). Pelvic floor muscle recovery and sexual satisfaction rates were comparable between groups. The SE group demonstrated better post-treatment scores for urinary symptoms and quality of life related to urinary incontinence. TAM thickness remained unchanged in both groups. Quality of life and depression scores improved similarly across both groups post-treatment.</p><p><strong>Conclusion: </strong>While acupuncture paired with CSE did not greatly surpass CSE alone in all outcomes, it provided enhanced pain relief and similar psychological benefit. These findings suggest a potential role for integrative approaches in managing postpartum pelvic pain, though longer-term studies with more objective measures are needed.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"46 4","pages":"1009-1017"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shaofu Zhuyu decoction can inhibit the progression of endometriosis fibrosis through the transforming growth factor-β1/ smads signaling pathway mediated by 5' adenosine monophosphate-activated protein kinase.","authors":"L I Bingbing, Ding Meiqi, Chen Xiangying, L I Wenzhe, Wei Chao, Y U Bin, M A Xiaona, Sun Xinhui","doi":"10.19852/j.cnki.jtcm.2026.04.004","DOIUrl":"https://doi.org/10.19852/j.cnki.jtcm.2026.04.004","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the mechanisms by which Shaofu Zhuyu decoction (SFZYD, ) modulates fibrosis in a mouse model of endometriosis.</p><p><strong>Methods: </strong>Mice were divided into control, endometriosis model, low-dose SFZYD, high-dose SFZYD, and dinorgestrel groups. Ectopic lesion weights and volumes were evaluated post-intervention. Uterine or lesion morphology and fibrosis were assessed using hematoxylin/eosin and Masson's trichrome and Sirius red staining, respectively. Gene expression levels of 5' adenosine monophosphate-activated protein kinase (AMPK), transforming growth factor β1 (TGF-β1), collagen type 1 alpha 1 chain (COL1A1), alpha smooth muscle actin (α-SMA), and connective tissue growth factor (CTGF) were detected using quantitative real-time polymerase chain reaction. Protein expression levels of AMPK, p-AMPK, TGF-β1, Smad2/3, p-Smad2/3, COL1A1, α-SMA and CTGF were detected using immunohistochemistry or Western blotting.</p><p><strong>Results: </strong>Staining revealed excessive ectopic lesion fibrosis, and p-AMPK/AMPK expression was downregulated in the model group, whereas TGF-β1, Smad2/3, COL1A1, α-SMA, and CTGF expression was upregulated. SFZYD-L group showed the greatest effect in reducing ectopic lesion size and inhibiting fibrosis. These changes were correlated with the activation/ phosphorylation of AMPK, suppression of TGF-β1 and Smad2/3 expression, and downregulation of COL1A1, α-SMA, and CTGF expression, suggesting a potential association with AMPK modulation.</p><p><strong>Conclusion: </strong>SFZYD significantly inhibits both the progression of ectopic lesions and the development of fibrosis in a mouse model of endometriosis. These effects are potentially mediated through the regulation of the AMPK/TGF-β1/Smads signaling pathway.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"46 4","pages":"809-820"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148814827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paeonol's protective effects on H9C2 cells against hypoxia/ reoxygenation injury through the hypoxia-inducible factor 1-alpha/B-cell lymphoma-2/adenovirus E1B 19 kDa interacting protein 3 signaling pathway.","authors":"Zhao Chengguo, Yin Meifang, Zhou Menghan, Qin Shuzhi","doi":"10.19852/j.cnki.jtcm.2026.04.001","DOIUrl":"10.19852/j.cnki.jtcm.2026.04.001","url":null,"abstract":"<p><strong>Objective: </strong>To elucidate the cytoprotective capacity of paeonol (PAE) against hypoxia/reoxygenation (H/R) injury in H9C2 cardiomyoblasts and to clarify its regulatory effects on the hypoxia-inducible factor 1-alpha (HIF-1α) and B-cell lymphoma-2/adenovirus E1B 19 kDa interacting protein 3 (BNIP3) signaling axis governing autophagy and apoptosis.</p><p><strong>Methods: </strong>H9C2 cells were exposed to a 12-h hypoxia condition followed by a 12-h reoxygenation regimen to simulate myocardial ischemia-reperfusion injury (MIRI). PAE pretreatment (10 μmol/L) was administered to cells before the H/R procedure. The viability of cells was determined using the cell counting kit-8 assay, whereas apoptotic rates were quantified <i>via</i> flow cytometry. Reactive oxygen species (ROS) levels were assayed by 2',7'-dichlorodihydrofluorescein diacetate fluorescence staining. Western blotting was conducted to assess protein expression, including cleaved caspase-3, and the ratio of Bcl-2-associated X protein to B-cell lymphoma 2 (Bax/Bcl-2), as well as microtubule- associated protein 1 light chain 3 (LC3) and sequestosome-1 (p62), along with components of the HIF-1α/BNIP3 signaling pathway. Autophagosomes were visualized by transmission electron microscopy. To elucidate the regulatory mechanisms, siRNA was used to knockdown HIF-1α expression, while the autophagy inhibitor 3-methyladenine (3-MA) was employed as a functional intervention.</p><p><strong>Results: </strong>PAE significantly improved cell viability following H/R treatment and inhibited apoptosis, as indicated by a reduction in cleaved caspase-3 levels and a decreased Bax/Bcl-2 ratio, along with diminished intracellular ROS levels. PAE treatment enhanced autophagosome formation and increased LC3-II levels, suggesting enhanced autophagic flux. Additionally, PAE upregulated the expression of HIF-1α and BNIP3. Silencing HIF-1α or inhibiting autophagy with 3-MA reversed the protective effects of PAE on autophagic flux, apoptosis, and cell viability.</p><p><strong>Conclusion: </strong>PAE protects H9C2 cells against H/R injury by promoting autophagy and inhibiting apoptosis, mediated through the upregulation of the HIF-1α/BNIP3 signaling pathway. These observations highlight the therapeutic implications of PAE for MIRI, particularly through targeting the HIF-1α/BNIP3 axis.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"46 4","pages":"779-787"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Jianchang No. 1 (1) formula alleviates irritable bowel syndrome with diarrhea improving gut microbiota and regulating toll-like receptors/nuclear factor-kappa B signaling pathway in bowel syndrome with diarrhea rats.","authors":"Liu Yutong, Yang Yan, X U Huiying, L I Lei, G E Fei, Chen Meijuan","doi":"10.19852/j.cnki.jtcm.2026.04.009","DOIUrl":"10.19852/j.cnki.jtcm.2026.04.009","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the therapeutic efficacy of Jianchang No. 1 (1) in treating irritable bowel syndrome with diarrhea (IBS-D) and to explore its underlying mechanisms of action.</p><p><strong>Methods: </strong>IBS-D rat models were established through a combination of chronic restraint stress, water avoidance stress, and the administration of senna decoction. Body weight, fecal water content (FWC), and intestinal capacity threshold in IBS-D rats were monitored before and after treatment. Pathological alterations in colon tissue were examined using hematoxylin and eosin staining. Serum levels of lipopolysaccharide (LPS), along with LPS content in colon tissue were measured using the enzyme-linked immunosorbent assay. 16S rRNA sequencing technology was employed to assess the abundance and compositional shifts within the gut microbiota. Quantitative real-time polymerase chain reaction, Western blot, and immunofluorescence were employed to determine gene and protein expression in colonic samples.</p><p><strong>Results: </strong>Jianchang No. 1 treatment restored body weight, lowered FWC, and raised the intestinal capacity threshold in IBS-D rats. Meanwhile, Jianchang No. 1 enhanced both the richness and composition of the gut microbiota. Moreover, Jianchang No. 1 markedly upregulated the tight-junction proteins zonula occludens-1 and occludin together with the anti-inflammatory cytokine interleukin-10, while simultaneously downregulating the LPS-toll-like receptor (TLR) 2/4- myeloid differentiation factor 88- nuclear factor kappa B (NF-κB) axis and the downstream pro-inflammatory mediators interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, together with interleukin-4 and interferon-gamma.</p><p><strong>Conclusions: </strong>Jianchang No. 1 maintains intestinal barrier integrity by reshaping gut-microbial diversity and composition, dampening the TLR/NF-κB signaling cascade, and thereby alleviating low-grade colonic inflammation and its attendant clinical symptoms in IBS-D rats.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"46 4","pages":"883-893"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yigongsan decoction ameliorates anemia of chronic disease by attenuating mothers against decapentaplegic homolog-signal transducer and activator of transcription 3 interaction to regulate iron homeostasis.","authors":"Zheng Qin, Zhu Xiaoqin, H U Jie, B U Jingyang, J I Yuting, Jiang Yiling, Shi Ling, Zhang Aiping, W U Zhihao, X U Haitao, Zhang Ruifeng, Yang Yang, Luo Meihong","doi":"10.19852/j.cnki.jtcm.2026.04.005","DOIUrl":"10.19852/j.cnki.jtcm.2026.04.005","url":null,"abstract":"<p><strong>Objective: </strong>To investigate how Yigongsan decoction (YGS) regulates iron metabolism in anemia of chronic disease (ACD) by modulating the hepcidin-ferroportin axis, with particular focus on crosstalk between the mothers against decapentaplegic homolog (SMAD) and signal transducer and activator of transcription 3 (STAT3) signaling pathways.</p><p><strong>Methods: </strong><i>In vivo</i>: a lipopolysaccharide (LPS)-induced ACD mouse model was treated with YGS (15.413 g·kg^-1·d^-1) for 7 d. Iron metabolism was evaluated by measuring serum and splenic iron levels, as well as hepcidin antimicrobial peptide (HAMP) and ferroportin (Fpn) mRNA expression (quantitative real-time polymerase chain reaction, qRT-PCR), and protein-protein interactions (co-immunoprecipitation, Co-IP). <i>In vitro</i>: HepG2 cells were stimulated with interleukin-6 (IL-6) or activin B and treated with 10% YGS-medicated serum. Iron metabolism was evaluated by intracellular and extracellular iron. STAT3/SMAD pathway activity was assessed by siRNA knockdown, Western blotting of phosphorylated SMAD1/5/8 (p-SMAD1/5/8) and phosphorylated STAT3 (p-STAT3), and Co-IP.</p><p><strong>Results: </strong>LPS-treated mice, YGS significantly decreased splenic iron content (<i>P <</i>0.01) and increased serum iron levels (<i>P <</i>0.05). Hepatic HAMP mRNA was downregulated, while Fpn mRNA was upregulated. In HepG2 cells, YGS counteracted IL-6/activin B-induced dysregulation, reducing hepcidin and intracellular iron while increasing ferroportin and extracellular iron. siRNA experiments confirmed that YGS restored the hepcidin-ferroportin balance independently of direct SMAD or STAT3 inhibition. Co-IP and immunofluorescence revealed that YGS attenuated the competitive interaction between phosphorylated SMAD1/5/8 (p-SMAD1/5/8) and phosphorylated STAT3 (p-STAT3), reducing their nuclear co-localization and subsequent HAMP transcription.</p><p><strong>Conclusion: </strong>Our results suggest that YGS may alleviate ACD by attenuating the interaction between the SMAD and STAT3 pathways, which appears to lead to reduced STAT3 phosphorylation and hepcidin expression, thereby re-establishing iron homeostasis. This identifies YGS as a potential therapeutic agent targeting inflammation-induced iron dysregulation.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"46 4","pages":"821-831"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Biling Weitong granules on gastrointestinal motility and gastrointestinal hormones levels in rats with functional dyspepsia.","authors":"Gao Lige, L I Xueyi, Chen Feiyu, Jiang Changyu, L I Jiadi","doi":"10.19852/j.cnki.jtcm.2026.04.007","DOIUrl":"10.19852/j.cnki.jtcm.2026.04.007","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of Biling Weitong granules on gastrointestinal motility and serum mouse motilin/human vasoactive intestinal peptide (MTL/VIP) enzyme-linked immunosorbent assay kit levels in functional dyspepsia (FD) rat models, and explore its therapeutic mechanisms against FD to provide further clinical application data.</p><p><strong>Methods: </strong>Sixty Sprague-Dawley rats were randomized into blank group (BG) and model group (MG). FD was induced in MG <i>via</i>30-d chronic unpredictable stress. After successful modeling, the model rats were divided into MG BG, Biling Weitong granules low/middle/high-dose (BL/BM/BH), and trimebutine maleate (TM) groups (<i>n =</i> 7/group) for 14-d treatments. At the end of the gavage, General parameters (body weight, food intake), gastrointestinal motility indices (gastric emptying and small intestinal propulsion rates), serum MTL/VIP levels, and gastric antrum histopathology were analyzed using hematoxylin and eosin (HE) staining.</p><p><strong>Results: </strong>After 30 d of modeling, compared with the BG group, rats in the MG group presented FD-like symptoms such as lethargy and irritability, along with significantly decreased body weight and food intake (<i>P <</i> 0.05). The gastric emptying rate and small intestinal propulsion rate were significantly reduced (<i>P <</i> 0.01), and the serum MTL content significantly decreased (<i>P <</i> 0.01). Serum VIP levels were significantly increased (<i>P <</i> 0.01). After 14 d of treatment, compared with the MG group, rats in the BL, BM, BH, and TM groups exhibited improved general condition, with significantly increased body weight and food intake (<i>P <</i> 0.05); significantly faster gastric emptying rate and small intestinal propulsion rate (<i>P <</i> 0.01); and significantly higher serum MTL content (<i>P <</i> 0.01). The serum VIP levels were significantly decreased (<i>P <</i> 0.01). There were no significant differences in body weight or food intake between the BM group and BH group (<i>P ></i> 0.05). Consistently, there were no significant differences in gastric emptying rate, small intestinal propulsion rate, or serum MTL and VIP contents between the BH and TM groups (<i>P ></i> 0.05). HE staining revealed no marked changes in the gastric antrum tissues of the BG, MG, or drug groups.</p><p><strong>Conclusion: </strong>Biling Weitong granules can modulate the levels of the gastrointestinal hormones MTL and VIP in FD rats, promote gastric emptying and small intestinal propulsion, improve the gastrointestinal motility and mental status of FD rats, and alleviate the symptoms of FD, accounting for its efficacy against FD.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"46 4","pages":"864-872"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered amino acids and acylcarnitines profile in infantile intrahepatic cholestasis liver disease: implication for Traditional Chinese Medicine syndrome differentiation.","authors":"Qiu Yanyan, Xia Yu, L I Weiwei, Yan Suqi, Pang Yusheng","doi":"10.19852/j.cnki.jtcm.2026.04.019","DOIUrl":"10.19852/j.cnki.jtcm.2026.04.019","url":null,"abstract":"<p><strong>Objective: </strong>To explore the diagnostic efficacy of blood amino acids (AAs) and acylcarnitines (ACs) profiles as metabolic biomarkers for differentiating Traditional Chinese Medicine (TCM) syndromes in infantile intrahepatic cholestatic liver disease (IICLD).</p><p><strong>Methods: </strong>Blood samples were collected from a cohort comprising 50 healthy controls and 77 patients diagnosed with IICLD, including 43 cases categorized as cold-damp obstruction and stagnation syndrome (COS) and 34 cases as jaundice due to stasis and accumulation syndrome (JSA) based on TCM diagnostic criteria. Metabolomic analyses targeting AAs and ACs were performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS).</p><p><strong>Results: </strong>Compared with the healthy controls group, the IICLD group showed 23 upregulated and 2 downregulated metabolites with a screening threshold of variables of importance in projection (VIP) ≥ 1, fold change (FC) ≥ 1.2 or ≤ 0.83, and <i>P <</i>0.05. Six different metabolites were screened between the COS group and JSA group with a screening threshold of VIP ≥ 1, FC ≥ 1.2 or ≤ 0.83, and <i>P <</i>0.05. Ornithine (Orn), Decanedioy lcarnitine (C10DC), Caproylcarnitine (C6) were identified as potential biomarkers for distinguishing between the two syndromes with VIP > 2, FC ≥ 1.2 or ≤ 0.83 and <i>P <</i>0.05; The areas under the receiver operating characteristic curves (AUC) for these biomarkers were Orn (AUC = 0.7394), C10DC (AUC = 0.7777), and C6 (AUC = 0.686). When the levels of these three biomarkers were combined, the AUC increased to 0.922.</p><p><strong>Conclusion: </strong>Distinct alteration of AAs and ACs profile highlighted the oxidative stress and mitochondrial impairment in IICLD. A combined set of metabolites (Orn+ C10DC+ C6) emerged as valuable biomarker for differentiating between the COS syndrome and JSA syndromes, providing a biochemical basis for syndrome differentiation.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"46 4","pages":"1000-1008"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}